Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GSK5764227 (Anti-B7H3 Antibody Drug Conjugate) Monotherapy or in Combination With Dostarlimab in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): a Multiomic Evaluation of Biomarkers of Response and Resistance (BeeHive)

NCT07408063 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT07408063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07408063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GSK5764227 (Anti-B7H3 Antibody Drug Conjugate) Monotherapy or in Combination With Dostarlimab in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): a Multiomic Evaluation of Biomarkers of Response and Resistance (BeeHive)
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Recruiting
Start date
April 27, 2026
Completion date
March 1, 2031
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent/metastatic head and neck squamous cell carcinoma